GlassScriptPhysician profile
Kausar Khan
NPI 1194490359
$10,542.36
in general payments reported to CMS, 2019-2025
48 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $1,885 · 2023: $3,083 · 2024: $3,140 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,496 · Education: $27.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,496.26 |
| Education | $27.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,676.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,157.58 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $960.80 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $950.44 | 2021-2025 | Bevespi Aerosphere, Breztri, Airsupra |
| Lilly USA, LLC | $796.03 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $475.16 | 2022-2025 | Verquvo, Belsomra, Gardasil 9 |
| Amgen INC. | $370.23 | 2022-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.70 | 2021-2025 | Jardiance, Stiolto Respimat |
| Corcept Therapeutics | $275.71 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $270.60 | 2022-2025 | |
| Pfizer INC. | $268.03 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $250.78 | 2022-2025 | Xarelto, Spravato |
| Astellas Pharma US INC | $245.78 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.02 | 2022-2025 | Caplyta |
| Lundbeck LLC | $231.77 | 2023-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kausar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.